Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel

Company achieves milestone of its first U.S. regulatory filing for a medical device FRAMINGHAM, MA ARTH, (Marketwired Jul 25, 2017) Arch Therapeutics, Inc. (OTCQB: ARTH) ( Arch or the Company ), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its AC5™ Topical Gel on July 17, 2017. If the Company s 510(k) application is cleared by the FDA, it is expected
http://bit.ly/2tWwNc4